Related posts

13 Recession-Proof Stocks for Portfolio SafetyStocks climb to start weekWinning and losing stocks and sectors
Investor Insights

This summary was created by AI, based on 41 opinions in the last 12 months.

Experts have varied opinions regarding Johnson & Johnson (JNJ-N). Some believe that the company is facing challenges due to recent litigation, especially over their talcum powder, while others see potential for growth in the pharmaceutical and medical devices divisions. The spinoff of the consumer products business has also evoked mixed reactions. Despite concerns, the company's strong balance sheet and dividend yield are highlighted, along with the potential for a stock re-rating. The stock is currently trading at an attractive valuation, with potential catalysts in the future.

Consensus
Mixed
Valuation
Fair Value
COMMENT
Johnson & Johnson

They report Tuesday. If they announce any resolution in the talcum powder lawsuits, this stock will jump 10 points.

biotechnology / pharmaceutical
BUY
Johnson & Johnson
Trevor Rose’s Insights - Trevor’s most-liked answers from 5i Research

JNJ offered its shareholders the opportunity to exchange JNJ shares for shares in Kenvue. The exchange was voluntary, and the exchange ratio was 8.03. Since this was an exchange of shares rather than just a pure distribution of the spinoff, the price of JNJ shares should not be as effected, since the company received JNJ shares from its shareholders, and effectively removed them from circulation, similar to a buyback. In effect, this causes the existing shareholders to own a larger piece of JNJ. 

JNJ is near the same price where the spinout took place, and some of the price decline in JNJ can be attributed to the broader healthcare sector. If the healthcare sector continues to improve from here, we expect JNJ will also participate in this rally. 
Unlock Premium - Try 5i Free

biotechnology / pharmaceutical
PAST TOP PICK
Johnson & Johnson

(A Top Pick Dec 28/22, Down 9%)

Recently sold shares. Spinoff of consumer products business has not gone well. Stock not performing well. Recent litigation is a big worry. 

biotechnology / pharmaceutical
BUY
Johnson & Johnson

Medical devices are an important area that keeps people out of expensive hospitals, improves quality of life, and reduces reliance on drugs. Great advances, which will grow over the years. You want to be in this area. He owns SYK and JNJ in the space.

biotechnology / pharmaceutical
SELL
Johnson & Johnson

Looking back on 2023: JNJ has one of the best pharma pipelines in the business. However, he sold it because he got tired on their many lawsuits over baby powder (having traces of asbestos, allegedly). Originally, he concluded that the company didn't know about the asbestos, but then the lawsuits piled up. JNJ offered to settle with claimants. He bought this for the fundamentals, but then it became about the settlements amounting to billions. There are easier ways to make money. He eventually sold.

biotechnology / pharmaceutical
BUY
Johnson & Johnson

Has long owned this. Got upgraded today. Pays a 3% dividend yield and trades at 15x forward PE. Healthcare will improve in 2024.

biotechnology / pharmaceutical
HOLD
Johnson & Johnson

Lots in pharma going off-patent around 2025, but pipeline's pretty good. Medical devices suffering from weight loss drugs meaning fewer joint replacements, but this fear is overdone. Talc litigation overhang, stock should lift once gone. Attractive multiple of 15x, AAA balance sheet. Yield is 3.2%.

biotechnology / pharmaceutical
COMMENT
Johnson & Johnson

The dynamics have changed. They sold off the personal care division and can now spend money on pharma and medical devices. They pay a good dividend which is increased regularly. The lawsuits including the one related to talcum powder holds it down but it trades at a good multiple,

biotechnology / pharmaceutical
PAST TOP PICK
Johnson & Johnson
(A Top Pick Oct 10/22, Down 7%)

Has sold shares in company. Does not own anymore. Breakdown in support. Moved on to greener pastures. 

biotechnology / pharmaceutical
BUY
Johnson & Johnson

It is now left with the pharmaceutical and medical devices divisions. The overhang is some litigation but it has a triple A balance sheet and recent earnings are good. The yield is good and it is attractively priced so buy for both growth and income.

biotechnology / pharmaceutical
TOP PICK
Johnson & Johnson

They're having a terrible year, but the PE is now cheap. They sold off their consumer division. Their last quarter they beat earnings: medical devices grew 10% and pharma 4.5%. Will continue to grow. Have a lot of cash. Have raised their dividend for 45 years, which will continue. One issue is their talcum powder [lawsuits over their talcum causing cancer], but they will appeal the ruling. Their psoriasis drug is coming off-patent, but they have enough in their drug pipeline to make up for that.

(Analysts’ price target is $177.43)
biotechnology / pharmaceutical
TOP PICK
Johnson & Johnson

A trade, because it's stuck in a trading range, between $160-180.

(Analysts’ price target is $179.43)
biotechnology / pharmaceutical
TOP PICK
Johnson & Johnson

A growth story. Split off consumer business, so can now focus on pharma and medical devices, which both had high growth profiles. Stock should re-rate. Dividend aristocrat. Yield is 3.02%.

(Analysts’ price target is $179.43)
biotechnology / pharmaceutical
PAST TOP PICK
Johnson & Johnson

(A Top Pick May 26/22, Down 8%)

He targets $193.75 or 21% higher. It pays a 3% dividend yield. It will likely outperform in a market downturn. Is waiting for them to spin off their vaccine business. Many positives here. A great defensive name.

biotechnology / pharmaceutical
Showing 1 to 15 of 583 entries

Johnson & Johnson(JNJ-N) Rating

Ranking : 5 out of 5

Bullish - Buy Signals / Votes : 20

Neutral - Hold Signals / Votes : 1

Bearish - Sell Signals / Votes : 5

Total Signals / Votes : 26

Stockchase rating for Johnson & Johnson is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Johnson & Johnson(JNJ-N) Frequently Asked Questions

What is Johnson & Johnson stock symbol?

Johnson & Johnson is a American stock, trading under the symbol JNJ-N on the New York Stock Exchange (JNJ). It is usually referred to as NYSE:JNJ or JNJ-N

Is Johnson & Johnson a buy or a sell?

In the last year, 26 stock analysts published opinions about JNJ-N. 20 analysts recommended to BUY the stock. 5 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Johnson & Johnson.

Is Johnson & Johnson a good investment or a top pick?

Johnson & Johnson was recommended as a Top Pick by on . Read the latest stock experts ratings for Johnson & Johnson.

Why is Johnson & Johnson stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Johnson & Johnson worth watching?

26 stock analysts on Stockchase covered Johnson & Johnson In the last year. It is a trending stock that is worth watching.

What is Johnson & Johnson stock price?

On 2024-02-23, Johnson & Johnson (JNJ-N) stock closed at a price of $161.84.